» Articles » PMID: 26881339

The Prevalence and Predictors of Bipolar and Borderline Personality Disorders Comorbidity: Systematic Review and Meta-analysis

Overview
Journal J Affect Disord
Date 2016 Feb 17
PMID 26881339
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Data about the prevalence of borderline personality (BPD) and bipolar (BD) disorders comorbidity are scarce and the boundaries remain controversial. We conducted a systematic review and meta-analysis investigating the prevalence of BPD in BD and BD in people with BPD.

Methods: Two independent authors searched MEDLINE, Embase, PsycINFO and the Cochrane Library from inception till November 4, 2015. Articles reporting the prevalence of BPD and BD were included. A random effects meta-analysis and meta-regression were conducted.

Results: Overall, 42 papers were included: 28 considering BPD in BD and 14 considering BD in BPD. The trim and fill adjusted analysis demonstrated the prevalence of BPD among 5273 people with BD (39.94 ± 11.78 years, 44% males) was 21.6% (95% CI 17.0-27.1). Higher comorbid BPD in BD were noted in BD II participants (37.7%, 95% CI 21.9-56.6, studies=6) and North American studies (26.2%, 95% CI 18.7-35.3, studies=11). Meta regression established that a higher percentage of males and higher mean age significantly (p<0.05) predicted a lower prevalence of comorbid BPD in BD participants. The trim and fill adjusted prevalence of BD among 1814 people with BPD (32.22 ± 7.35 years, 21.5% male) was 18.5% (95% CI 12.7-26.1).

Limitations: Paucity of longitudinal/control group studies and accurate treatment records.

Conclusions: BPD-BD comorbidity is common, with approximately one in five people experiencing a comorbid diagnosis. Based on current diagnostic constructs, and a critical interpretation of results, both qualitative and quantitative syntheses of the evidence prompt out the relevance of differences rather similarities between BD and BPD.

Citing Articles

Rebuilding the Evidence on the use of Lithium for Borderline Personality Disorder.

Almeida T, Sanches M Clin Neuropsychiatry. 2025; 21(6):550-552.

PMID: 39839598 PMC: 11745036. DOI: 10.36131/cnfioritieditore20240608.


Dynamics of affect modulation in neurodevelopmental disorders (DynAMoND) - study design of a prospective cohort study.

Bayas M, Kockler T, Ramos-Quiroga J, Caller S, Fadeuilhe C, de Girolamo G Int J Bipolar Disord. 2024; 12(1):44.

PMID: 39733204 PMC: 11682027. DOI: 10.1186/s40345-024-00367-2.


The Role of Oxytocin and Vasopressin in People with Borderline Personality Disorder: A Closer Look at Adolescents.

Uzar M, Dmitrzak-Weglarz M, Slopien A Int J Mol Sci. 2024; 25(22).

PMID: 39596113 PMC: 11593878. DOI: 10.3390/ijms252212046.


The association between borderline personality disorder, childhood trauma, neuroticism, and self-rated or clinician-rated functional impairment in euthymic bipolar disorder-1 patients.

Aydin E, Koca Lacin T Front Psychiatry. 2024; 15:1444583.

PMID: 39450306 PMC: 11499097. DOI: 10.3389/fpsyt.2024.1444583.


Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series.

Francis B, Ganasan V, Sulaiman A Medicina (Kaunas). 2024; 60(2).

PMID: 38399570 PMC: 10890360. DOI: 10.3390/medicina60020283.